Table 1.
Incidence of IMD by country and serogroup and associated new vaccination recommendations
| Country | Year | Number and/or percentage of IMD cases by serogroup | Preceding meningococcal vaccine recommendation; age group | Year current MenACWY vaccine recommendation introduceda; age group | |||
|---|---|---|---|---|---|---|---|
| B | C | W | Y | ||||
| England [41] | 2016–2017 | 396 (53.0%) | 37 (5.0%) | 225 (30.1%) | 80 (10.7%) | MenC; infants, toddlers, adolescents [42, 65] | 2015; adolescents [42] |
| 2012–2013 | 595 (77.4%) | 33 (4.3%) | 55 (7.2%) | 75 (9.8%) | |||
| France [43, 44] | 2016 | 52%a | 26%b | 9%a | 12%a | MenC; infants, toddlers [45] | Not introduced [45] |
| 2015 | 242 (52.3%) | 119 (25.8%) | 32 (6.9%) | 54 (11.7%) | |||
| 2011 | 395 (70.2%) | 84 (14.9%) | 14 (2.5%) | 45 (8.0%) | |||
| Italy [44] | 2015 | 47 (25.1%) | 57 (30.5%) | 7 (3.7%) | 22 (11.8%) | MenC; toddlers [45, 46, 67] |
2015; adolescents, adultsc [66] 2017; adolescents [46] |
| 2011 | 75 (49.3%) | 19 (12.5%) | 4 (2.6%) | 16 (10.5%) | |||
| Netherlands [44, 47] | 2016 | 77 (50.1%) | 6 (4.0%) | 50 (33.1%) | 17 (11.3%) | MenC; toddlers [45, 48] | 2018; toddlers, adolescents [48] |
| 2015 | 65 (72.2%) | 8 (8.9%) | 9 (10.0%) | 7 (7.8%) | |||
| 2011 | 79 (74.5%) | 4 (3.8%) | 1 (0.9%) | 13 (12.3%) | |||
| Australia [49–51] | 2017 | 138 (36.0%) | 14 (3.7%) | 140 (36.6%) | 75 (19.6%) | MenC; toddlers [38, 68] |
2018; toddlers [38] 2019; adolescents [80] |
| 2015 | 108 (62.1%) | 2 (1.1%) | 36 (20.7%) | 22 (12.6%) | |||
| 2011 | 179 (74.3%) | 9 (3.7%) | 11 (4.6%) | 15 (6.2%) | |||
| Canada [52–54] | 2016 | NA | NA | 15 (18.8%) | NA |
MenC; infants, toddlers; adolescentsd |
By 2019 in almost all provinces and territoriese; adolescents [56, 81, 128] |
| 2015 | 63 (58%) | 4 (4%) | 6 (6.8%) | 25 (23%) | |||
| 2006–2011 | 669 (61.3%a) | 138 (12.6%a) | 62 (5.7%a) | 196 (17.9%a) | |||
| Argentina [58–60] | 2014f | 70 (47.0%) | 2 (1.3%) | 73 (49.0%) | 4 (2.7%) | NA | 2017; infants, adolescents [61, 62] |
| 2010 | 56 (41.8%) | 7 (5.2%) | 66 (49.3%) | 4 (3.0%) | |||
| 2006 | 46 (67.6%) | 5 (7.4%) | 4 (6.3%) | 5 (7.4%) | |||
| Chile [58–60, 63] | 2017 | 26 (32.5%) | 1 (1.3%) | 47 (58.8%) | 1 (1.3%) | NA | 2012; toddlers [39, 64, 69] |
| 2014 | 28 (23.5%) | 2 (1.7%) | 87 (73.1%) | 1 (0.8%) | |||
| 2010 | 36 (64.3%) | 8 (14.3%) | 6 (10.7%) | 4 (7.1%) | |||
| 2006 | 53 (67.9%) | 9 (11.5%) | 3 (4.5%) | 2 (2.6%) | |||
IMD invasive meningococcal disease, MenACWY meningococcal serogroups A, C, W, and Y, MenC meningococcal serogroup C, NA not available
aNational and regional recommendations shown; does not include recommendations for at-risk populations or from medical societies
bPercentage of cases with serogroup information
cTuscany region
dDepending on province/territory
eWith the exception of Quebec
fPercentages are based on the total number of serogroup B, C, W, and Y isolates